Aflac Delivers Strong FY25 Amid Rapid Japan Sales Growth (AFL Q4 2025 Earnings Call)

By Dr. Graph | Updated on Apr 29, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Aflac Incorporated posted a highly resilient close to 2025, marked by extraordinary shareholder returns and accelerating sales momentum in its core Japanese and U.S. markets. Leveraging the phenomenal success of new product launches in Japan and robust group sales expansion domestically, the supplemental insurance giant proved its ability to navigate macroeconomic shifts while maintaining top-tier persistency. Bolstered by a massively fortified balance sheet and an aggressive capital deployment strategy, Aflac continues to cement its reputation as a defensive, highly cash-generative compounding machine heading into 2026.

Record Capital Returns and Solid Earnings Delivery

Aflac concluded the year with a robust financial performance, reporting fourth-quarter net earnings per diluted share of $2.64 and adjusted earnings of $1.57. For the full year, the company delivered net earnings of $6.82 and adjusted earnings of $7.49 per share. The company demonstrated an aggressive commitment to creating shareholder value by deploying a record $3.5 billion to repurchase thirty-three million shares, alongside paying $1.2 billion in cash dividends. This resulted in a massive $4.8 billion in total capital returned to shareholders during the year. Operational metrics remained highly resilient across geographies; Japan sales surged 15.7% in the final quarter with a stellar premium persistency of 93.1%, while the U.S. segment generated nearly $1.6 billion in new annual sales and maintained a strong persistency rate of 79.2%.

Optimistic 2026 Guidance and Dividend Growth

Looking ahead to 2026, management outlined a highly disciplined financial framework. In Japan, underlying earned premiums are expected to decline by one to two percent, with the benefit ratio projected between 60% and 63%, supporting a robust pretax margin of 33% to 36%. In the United States, net earned premium growth is forecasted at the lower end of a three to six percent range, anticipating a benefit ratio between 48% and 52% and a pretax margin ranging from 17% to 20%. Highlighting enduring financial confidence, the Board of Directors approved a 5.2% increase to the first-quarter dividend, marking forty-three consecutive years of dividend growth for the insurer.

Product Innovation Fuels Cross-Border Growth

Sales momentum was heavily driven by successful product innovations in both major markets. In Japan, the recently launched "Miraito" cancer insurance product was wildly successful, catalyzing a staggering 35.6% increase in specific cancer product sales, complemented by the timely September repricing of its "Tsumitasu" savings product. In the U.S., group and supplemental health products experienced explosive demand: network dental sales skyrocketed 48.8%, life and disability lines expanded by 11.3%, and the direct-to-consumer platform grew 10.5%. Capital flexibility was further optimized as the company reduced its minimum holding company liquidity target by $750 million down to one billion dollars, bolstered by off-balance-sheet facilities, while maintaining an exceptionally strong U.S. combined risk-based capital (RBC) ratio estimated at 575%.

Q&A Unveils Bermuda Reinsurance and AI Advancements

During the Q&A, analysts focused heavily on capital positioning and operational efficiencies. Management clarified that Japan's estimated Economic Solvency Ratio stands at an incredibly healthy 253%, which includes an 18-point uplift from undertaking specific parameters (USP). Executives also detailed a massive one hundred thirty basis point reduction in Japan’s net premium ratio expected for the upcoming year due to structural actuarial updates. When questioned on technology, leadership highlighted that over sixty percent of traditional U.S. claims are now processed using artificial intelligence and machine learning assistance, though humans retain final adjudication authority. Finally, they confirmed having ceded six percent of the Japan balance sheet to their Bermuda affiliate, with an active midterm target to reach ten percent.

Frequently Asked Questions

How much capital did Aflac return to shareholders in 2025?

The company deployed a record $3.5 billion toward share repurchases and paid out $1.2 billion in dividends, equating to a massive combined capital return of $4.8 billion for the full year.

What drove the exceptional sales growth in Aflac's Japan segment?

The 15.7% surge in fourth-quarter sales was primarily ignited by the highly successful launch of "Miraito," a newly formulated cancer insurance product that resonated deeply with consumers seeking protection against rising out-of-pocket medical expenses.

How is Aflac utilizing Artificial Intelligence in its operations?

Aflac is aggressively integrating machine learning and AI into its claims processing. Currently, over sixty percent of traditional U.S. claims utilize AI-assisted adjudication recommendations, driving major efficiency gains while preserving human oversight for final decisions.